A number of 15 patients will be included to assess the efficacy of donor regulatory enriched T cells in steroid-refractory chronic graft versus host disease patients who did not obtain complete remission after 12 weeks of treatment with ruxolitinib.~The doses of Treg-enriched cells will be 2x10^6 cells/kg.~Survival at 1 year after Treg infusion will be represented based on the clinical data with Kaplan Meier curves.
Phase II clinical trial to assess the efficacy of donor regulatory enriched T cells in steroid-refractory chronic graft versus host disease patients who did not obtain complete remission under treatment with ruxolitinib